To demonstrate that ARQ 092 and ARQ 751 are effective against AKT1-E17K mutations in vivo we tested them in PDX models from an endometrial tumor harboring the AKT1-E17K mutant and several other major mutations (ARID1A, BRCA1/2, TP53, APC). Here, ARID1A is linked to endometrium neoplasm.